Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $33.56 Average Price Target from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have been assigned an average rating of “Hold” from the twenty-eight ratings firms that are presently covering the company, MarketBeat reports. Six research analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $32.8462.

A number of brokerages have recently issued reports on SRPT. Barclays initiated coverage on Sarepta Therapeutics in a research report on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 target price on the stock. Jefferies Financial Group reissued a “buy” rating and issued a $30.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday. Loop Capital set a $25.00 price objective on Sarepta Therapeutics in a report on Tuesday. Wells Fargo & Company reduced their price objective on shares of Sarepta Therapeutics from $45.00 to $38.00 and set an “overweight” rating for the company in a research note on Friday, February 27th. Finally, Royal Bank Of Canada increased their target price on Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a report on Thursday, January 8th.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of Sarepta Therapeutics stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total transaction of $294,201.97. Following the sale, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at approximately $4,312,523. The trade was a 6.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.60% of the stock is owned by company insiders.

Institutional Trading of Sarepta Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SRPT. AQR Capital Management LLC lifted its position in shares of Sarepta Therapeutics by 214.2% in the first quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company’s stock valued at $344,000 after buying an additional 3,671 shares during the last quarter. Great Lakes Advisors LLC bought a new stake in Sarepta Therapeutics in the 1st quarter valued at $224,000. State of New Jersey Common Pension Fund D raised its stake in Sarepta Therapeutics by 59.9% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 48,555 shares of the biotechnology company’s stock valued at $830,000 after acquiring an additional 18,190 shares during the period. New York Life Investment Management LLC raised its stake in Sarepta Therapeutics by 10.0% in the 2nd quarter. New York Life Investment Management LLC now owns 10,623 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 966 shares during the period. Finally, Retirement Systems of Alabama lifted its holdings in Sarepta Therapeutics by 3.3% during the 2nd quarter. Retirement Systems of Alabama now owns 120,118 shares of the biotechnology company’s stock valued at $2,054,000 after purchasing an additional 3,859 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Trading Up 3.0%

Shares of NASDAQ:SRPT opened at $16.71 on Monday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.48 and a current ratio of 2.32. The stock has a market capitalization of $1.75 billion, a price-to-earnings ratio of -1.98, a PEG ratio of 0.24 and a beta of 0.42. Sarepta Therapeutics has a 1-year low of $10.41 and a 1-year high of $104.85. The company has a 50 day moving average price of $19.85 and a 200 day moving average price of $20.07.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($2.71). Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The company had revenue of $442.93 million during the quarter, compared to the consensus estimate of $390.95 million. During the same period in the prior year, the company posted $1.90 EPS. Sarepta Therapeutics’s quarterly revenue was down 32.7% on a year-over-year basis. On average, research analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.